Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.4%. By the end of trading, Celgene Corporation fell $4.36 (-2.6%) to $159.98 on average volume. Throughout the day, 3,352,606 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3,050,000 shares. The stock ranged in price between $159.35-$165.01 after having opened the day at $163.96 as compared to the previous trading day's close of $164.34. Other companies within the Drugs industry that declined today were:

Cerus Corporation



), down 17.2%,




), down 14.9%,

Biocryst Pharmaceuticals



), down 7.6% and

Jazz Pharmaceuticals



), down 7.4%.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene Corporation has a market cap of $66.6 billion and is part of the health care sector. Shares are down 2.9% year to date as of the close of trading on Tuesday. Currently there are 24 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Celgene Corporation

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front,

Anika Therapeutics



), up 33.2%,




), up 26.4%,

Prana Biotechnology



), up 19.9% and




), up 14.2% , were all gainers within the drugs industry with

Intercept Pharmaceuticals



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.